UnknownPhase 1/2

Ruxolitinib Combined With Dexamethasone for HLH

China50 participantsStarted 2017-03-01

Plain-language summary

A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Secondary and refractory HLH. Exclusion Criteria: * Family HLH.

Severity of disease

Timeframe: 2 weeks

NCT IDNCT03795909

SponsorCapital Research Institute of Pediatrics

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2020-03-01

Yan Yue, MD